Inadequate Clinical Response to Sirukumab, an Anti-IL-6 Monoclonal Antibody, Can be Predicted after a Single Dose of Treatment in Patients with Rheumatoid Arthritis

被引：0

作者：

Daga, Shruti ^{[1
]}

Aletaha, Daniel ^{[2
]}

Hsu, Benjamin ^{[3
]}

Gilbride, Jennifer ^{[4
]}

Christie, Jacquie ^{[5
]}

Loza, Matthew ^{[3
]}

Dasgupta, Bidisha ^{[3
]}

Campbell, Kim ^{[3
]}

Brown, Kurt ^{[6
]}

Rao, Ravi ^{[5
]}

Tak, Paul P. ^{[5
]}

机构：

[1] GlaxoSmithKline, Uxbridge, Middx, England

[2] Med Univ Vienna, Div Rheumatol, Dept Med 3, Vienna, Austria

[3] Janssen Res & Dev LLC, Spring House, PA USA

[4] Sum Sq Ltd, Walkern, Herts, England

[5] GlaxoSmithKline, Stevenage, Herts, England

[6] GlaxoSmithKline, Collegeville, PA USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2017年 / 69卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1478

引用

页数：3

共 50 条

[1] Integrated Phase 3 Safety Results of Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis
Aletaha, Daniel
Thorne, Carter
Schiff, Michael
Harigai, Masayoshi
Agarwal, Prasheen
Rao, Ravi
Cohen, Christopher
Cheng, Ben
Brown, Kurt
Hsu, Benjamin
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[2] Tocilizumab - A humanized anti-IL-6 receptor monoclonal antibody for the treatment of rheumatoid arthritis
Schlesselman, Lauren S.
Hussey, Aaron P.
FORMULARY, 2008, 43 (08) : 272 - 279
[3] Consistent Pharmacodynamic Effects of Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, on Serum Analytes Across Four Phase 3 Clinical Trials in Rheumatoid Arthritis
Loza, Matthew
Sweet, Kristen
Peffer, Nancy
Franks, Carol
Ma, Keying
Campbell, Kim
Sims, Martin
Dasgupta, Bidisha
ARTHRITIS & RHEUMATOLOGY, 2016, 68
[4] IMPACT OF ANTI-IL-6 MONOCLONAL ANTIBODY, CLAZAKIZUMAB, ON PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO METHOTREXATE IN A PHASE IIB STUDY
Alemao, E.
Joo, S.
Banerjee, S.
Emery, P.
Weinblatt, M.
L'ltalien, G.
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 947 - 947
[5] CLAZAKIZUMAB Humanized Anti-IL-6 Monoclonal Antibody Treatment of Rheumatoid Arthritis Treatment of Autoimmune Diseases Oncolytic
Reviriego, C.
DRUGS OF THE FUTURE, 2012, 37 (09) : 633 - 636
[6] In Vitro Cellular Profiling of Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, Reveals a Distinct Phenotypic Signature Compared to Tocilizumab, an Anti-IL-6 Receptor Monoclonal Antibody
Chavele, Konstantia-Maria
Gardner, Debbie
Loza, Matthew J.
Dasgupta, Bidisha
Sims, Martin
Shealy, David
Reid, Juliet
Rao, Ravi
ARTHRITIS & RHEUMATOLOGY, 2016, 68
[7] Network Meta-Analysis to Assess the Relative Efficacy of Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, in Combination Therapy for Patients with Active Rheumatoid Arthritis Despite Conventional Dmards
Peterson, Steve
Pacou, Maud
Belhadi, Drifa
Van Sanden, Suzy
Webb, Thomas
Ganguly, Rita
Kurrasch, Regina
Rao, Ravi
Hsu, Benjamin
Fei, Kaiyin
Kielar, Danuta
Alfonso, Rafael
ARTHRITIS & RHEUMATOLOGY, 2016, 68
[8] Anti-IL-6 receptor monoclonal antibody as a new treatment of endometriosis
El-Zayadi, Ahmed A.
Mohamed, Sara A.
Arafa, Mohammad
Mohammed, Shereen M.
Zayed, Abdelhady
Abdelhafez, Mohamed S.
Badawy, Ahmed M.
IMMUNOLOGIC RESEARCH, 2020, 68 (06) : 389 - 397
[9] Anti-IL-6 receptor monoclonal antibody as a new treatment of endometriosis
Ahmed A. El-Zayadi
Sara A. Mohamed
Mohammad Arafa
Shereen M. Mohammed
Abdelhady Zayed
Mohamed S. Abdelhafez
Ahmed M. Badawy
Immunologic Research, 2020, 68 : 389 - 397
[10] Determination of Heterogeneous Proteomic and Metabolomic Response in anti-TNF and anti-IL-6 Treatment of Patients with Rheumatoid Arthritis
Stepanov, Alexander A.
Malsagova, Kristina A.
Kopylov, Arthur T.
Rudnev, Vladimir R.
Karateev, Dmitry E.
Markelova, Evgenia I.
Luchikhina, Elena L.
Borisova, Elena E.
Kaysheva, Anna L.
LIFE-BASEL, 2023, 13 (02):

← 1 2 3 4 5 →